Skip to main content

Gore Acquires Pipeline Medical Technologies, Inc.

Acquisition of transcatheter mitral chordal repair technology builds on Gore’s structural heart capabilities

FLAGSTAFF, Ariz. (September 6, 2018) – W. L. Gore & Associates, Inc. (Gore) a global leader in providing solutions for cardiovascular disease, announced the acquisition of Pipeline Medical Technologies, Inc., a privately held medical technology company focused on advancing chordal repair for degenerative mitral regurgitation (DMR) via a transcatheter procedure.

“The addition of Pipeline's investigational technology and talented associates bolsters our continued ambition to improve patients’ lives by offering physicians innovative treatment solutions across the cardiac space,” said David Abeyta, Leader of Gore Medical Products Division. “Pipeline’s cutting-edge repair procedure, for patients with mitral valve disease, has the potential to expand Gore’s growing portfolio of treatments for structural heart disease, and it echoes our commitment to innovation across cardiac therapies.”

The Pipeline device is designed to replicate the outcomes of a highly effective surgical procedure via a catheter, avoiding the trauma and many of the risks associated with open heart surgery. “An entirely catheter-based, transfemoral and transseptal chordal repair will be an important tool for minimally invasive treatment of mitral regurgitation,” commented Paul Sorajja, MD, Director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute at Abbott Northwestern Hospital.

“We see an array of synergies working with Gore. The company is well recognized for its advanced material capabilities. Its long history of designing solutions for DMR treatment challenges already includes the GORE-TEX® Suture for Chordae Tendineae, used in surgical chordal repairs and we are excited to collaborate on future innovations in transcatheter mitral chordal repair,” said Pipeline founder Steven Bolling, MD, a leading mitral valve surgeon. “Together we aspire to significantly advance DMR patient outcomes and improve recovery speed.”

The company will retain the Pipeline name and operate independently of Gore as a wholly owned subsidiary. Pipeline’s device is currently in development and not available for commercial use.

* For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).


Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion.